Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.

Nonetheless, despite being in a more advanced stage of diabetes than users of other second- to third-line antidiabetic drugs, users of SGLT-2is still had lower all-cause mortality and an almost significant lower SCA risk.

also in 1,858 other papers

Use of SGLT-2i was associated with a reduced HR of SCA when compared with other second- to third-line antidiabetic drugs after adjustment for common SCA risk factors, although this association marginally failed to reach statistical significance [HR: 0.62, 95% confidence interval (95% CI): 0.38–1.01].

also in 6,035 other papers